URGN UroGen Pharma Ltd.
USHealthcareAs of 2026-07-10 11:27
Why URGN matters now
UroGen Pharma Ltd. (URGN) is a US stock in Healthcare. The latest InvestLog snapshot shows $38.89 with -3.33% on the session and $1.89B in market capitalization; recent performance reads 1-month +18.79% and YTD +43.34%.
The latest financial table shown here is Q1 2026, with revenue of $51.0M, net income of $-23.6M, and EPS of $-0.47. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -10.2%.
The latest indexable market news headline is "UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $42.50; recent insider activity includes Schoenberg Mark filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-13.56
P/S
11.64
EV/EBITDA
-14.87
DCF Value
$-30.55
FCF Yield
-10.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.9%
Operating Margin
-77.0%
Net Margin
-94.8%
ROE
121.5%
ROA
-52.5%
ROIC
-50.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.0M | $-23.6M | $-0.47 |
| Q4 2025 | $37.8M | $-26.4M | $-0.54 |
| FY 2025 | $109.8M | $-153.5M | $-3.19 |
| Q3 2025 | $27.5M | $-33.3M | $-0.69 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$42.50
Target (Median)
$42.50
Target Range
$40.00 - $45.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.62
UroGen Pharma Ltd. is a biotechnology firm dedicated to creating and marketing innovative treatments for specialized cancers and diseases affecting the urinary tract. Its proprietary technology includes RTGel, a biocompatible polymer with reverse thermal gelation properties designed to enhance the efficacy of existing medications. The company also markets Jelmyto, used in pyelocalyceal solutions. A key component of its pipeline is UGN-102, currently undergoing Phase III clinical trials. This investigational drug targets various forms of non-muscle invasive urothelial cancer, specifically low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. Additionally, UroGen is developing UGN-301 for high-grade non-muscle invasive bladder cancer. The company holds a licensing agreement with Allergan Pharmaceuticals International Limited, enabling the development and commercialization of pharmaceutical products incorporating both RTGel and clostridial toxins. It also partners with Agenus Inc. to advance, produce, and commercialize Agenus's products for intravesical delivery in urinary tract cancer treatment. Furthermore, a strategic research collaboration with MD Anderson aims to progress experimental treatments for high-grade bladder cancer. Established in 2004, UroGen Pharma Ltd. operates out of Princeton, New Jersey.